Moreover, while the safety, feasibility and potential efficacy of reovirus as a cancer therapy are currently being evaluated in multiple phase I-III clinical trials, the underlying molecular mechanism of by which reovirus preferentially induces oncolysis in KRAS mutant cells is not well understood. This evidence concerns the gene KRAS and cancer.